

## **Cardio Policy:**

# Wireless Pulmonary Artery Pressure Device Placement and Monitoring

POLICY NUMBER UM CARDIO_1402	SUBJECT Wireless Pulmonary Artery Pressure Device Placement and Monitoring		DEPT/PROGRAM UM Dept	PAGE 1 OF 3
<b>DATES COMMITTEE REVIEWED</b> 06/10/20, 06/14/21, 11/09/21, 08/10/22	APPROVAL DATE August 10, 2022	EFFECTIVE DATE August 26, 2022	COMMITTEE APPROVAL DATES 06/10/20, 06/14/21, 11/09/21, 08/10/22	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
URAC STANDARDS HUM v8: UM 1-2; UM 2-1	NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

#### I. PURPOSE

Indications for determining medical necessity for the implantation of a Wireless Invasive Pulmonary Artery Pressure Monitoring device and ongoing data collection.

### **II. DEFINITIONS**

Patients with chronic congestive heart failure (CHF), who have been hospitalized for this diagnosis are at an increased risk of rehospitalization, regardless of their left ventricular ejection fraction (LVEF). Since 2011, several studies have demonstrated a reduction in CHF hospitalizations through the method of following patient's pulmonary artery pressure (PAP) as a predictor of an impending CHF exacerbation and subsequent hospitalization.

This is an implantable PAP monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the PA. The sensor monitors changes in the PAPs and communicates via wireless to an external analyzer. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients.

Appropriate Use Criteria (AUC score) for a service is one in which the expected incremental information, combined with clinical judgment, exceeds the expected negative consequences by a sufficiently wide margin for a specific indication that the procedure is generally considered acceptable care and a reasonable approach for the indication. The ultimate objective of AUC is to improve

patient care and health outcomes in a cost-effective manner but is not intended to ignore ambiguity and nuance intrinsic to clinical decision making.

Appropriate Care- Median Score 7-9

May be Appropriate Care- Median Score 4-6

Rarely Appropriate Care- Median Score 1-3

#### III. POLICY

#### Indications for approving a request for medical necessity are:

- A. Patients with CHF of any LVEF type who have been hospitalized at least once over the prior year and still have Class III symptoms, and have been re-hospitalized with decreasing time intervals over the prior year, and have demonstrated chronically elevated mean PAP (>30 mmHg) and PCWP ≥ 20 mmHg by invasive means, or a PAS pressure >40 mmHg by echocardiography measured in between acute exacerbations and within 30 days of the intended Wireless Pulmonary Artery Pressure device implant, despite documented compliance with maximally tolerated guideline-directed medical therapy in conjunction with non-pharmacological adjuvant treatments (e.g. daily weights, dietary restrictions, VNS home visits) to prevent hospitalization for CHF. (AUC Score 4)¹,2,3,4
- B. Remote monitoring of the data is billable once per 30 days and must include at least once weekly downloads of pulmonary artery pressure recordings, interpretations(s), trend analysis, and report(s) by a physician or other qualified health care professional. (AUC Score 4)<sup>1,2,3,4</sup>

#### Limitations

- A. The Wireless Pulmonary Artery Pressure Device System is contraindicated for patients with:
  - 1. an inability to take dual antiplatelet or anticoagulants for one-month post implant
  - 2. Have a GFR < 25 cc/min or who are non-responsive to diuretic therapy or are on chronic renal replacement therapy
  - 3. Have a history of recurrent PE or DVT
  - 4. Have congenital heart disease
  - 5. Are likely to undergo heart transplantation or VAD placement within the next 6 months
- B. The patient must be followed by a heart failure team within the health care facility.
- C. Requests for services that are part of a surveillance protocol for patients who are involved in a clinical trial are considered out of scope (OOS) for New Century Health and cannot be reviewed.

#### IV. PROCEDURE

- A. In order to review a request for medical necessity, the following items must be submitted for review:
  - 1. Progress note that prompted request from Interventional Cardiologist/ Heart Failure
  - 2. Echocardiogram and right heart catheterization reports
- B. Primary codes appropriate for this service: Implantation of wireless PAP sensor monitor: 33289. For remote monitoring of an implantable wireless pulmonary artery pressure sensor monitor, use 93264
  - 1. Codes 93451 and 93568 are not to be used with 33289



2. If 93264 is being billed, then physiologic monitoring codes i.e. 93297 can no longer be used

#### V. APPROVAL AUTHORITY

- A. Review Utilization Management Department
- B. Final Approval Utilization Management Committee

#### **VI. ATTACHMENTS**

A. None

#### VII. REFERENCES

- CardioMEMS HF System Post Approval Study; ClinicalTrials.gov Identifier: NCT02279888; Study Completion Date: February 3, 2020; https://clinicaltrials.gov/ct2/show/study/NCT02279888
- Piotr Ponikowski, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC); Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128
- 3. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomized trial. Lancet 2016; 387:453–461.
- 4. Abraham, WT, Adamson, PB, Bourge, RC. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet 2011; 377: 658–666.
- 5. NCQA UM 2022 Standards and Elements.